Peptris Technologies Pvt Ltd.

Bengaluru: An AI-powered drug discovery company Peptris Technologies, has out-licensed the commercial rights of its preclinical rare disease candidate ‘ PEPR124 (RT001)’ to a biotech start-up Revio Therapeutics for an undisclosed amount. The two companies have entered into a licensing agreement under which Revio Therapeutics will hold commercialisation rights of the preclinical candidate in all markets except in BRICS countries, which will be retained by Peptris. “The agreement represents an important step in our mission to leverage AI-driven drug discovery for high-impact therapeutic advancements and Revio Therapeutics’ expertise in repurposing medicines will accelerate the clinical development of PEPR124 to benefit DMD patients,” the company statement reads. Peptris Technologies and Revio Therapeutics are looking to present the preclinical efficacy data as a Late-Breaking Poster at the Muscular Dystrophy Association (MDA) Conference, scheduled on Mar 16-19, 2025, in Dallas, Texas. In addition to this, the US biotech startup says that, “RT001 is well-positioned as a Phase 2-ready asset for development via the 505(b)(2)/hybrid pathway and we will discuss our development plans with the US FDA later this year at a pre-IND meeting and apply for an orphan drug designation .” DMD is a rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration , severe disability, and reduced life expectancy. As per Peptris PEPR124 (RT001) was discovered by using its proprietary AI-driven drug discovery platform and has demonstrated promising efficacy in preclinical studies for DMD. It is a repurposed, mutation-agnostic, and safe therapeutic that could be a significant breakthrough therapeutic for not only DMD but other muscular dystrophies as well, it added. By Online Bureau ,